HLA-DRB1*07:01 and *08:02 Alleles Confer a Protective Effect Against ACPA-Positive Rheumatoid Arthritis in a Latin American Admixed Population

Patricia Castro-Santos 1,2,†, Jordi Olloquequi 1,†, Ricardo A. Verdugo 3,4,*, Miguel A. Gutiérrez 5,6, Carmen Pinochet 7, Luis A. Quíñones 8,9,* and Roberto Díaz-Peña 1,*,†

1 Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Talca 3460000, Chile; patricassan@gmail.com (P.C.-S.); jordiog82@gmail.com (J.O.)
2 Inmunología, Centro de Investigaciones Biomédicas (CINBIO), Universidad de Vigo, 36310 Vigo, Spain
3 Programa de Genética Humana, ICBM, Facultad de Medicina, Universidad de Chile, Santiago 8389100, Chile; raverdugo@uchile.cl
4 Departamento de Oncología Básico-Clinico, Facultad de Medicina, Universidad de Chile, Santiago 8389100, Chile
5 Rheumatology, Almirante Nef Naval Hospital, Viña del Mar, Valparaíso 2340000, Chile; magutierrez2004@gmail.com
6 School of Medicine, Valparaíso University, Valparaíso 2340000, Chile
7 Hospital Regional de Talca, Talca 3460000, Chile; cmpinochet@gmail.com
8 Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic-Clinical Oncology, Faculty of Medicine, University of Chile, Santiago 8320000, Chile
9 Latin American Network for Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), 28015 Madrid, Spain
* Correspondence: lquinone@med.uchile.cl (L.A.Q.); roberto.diaz.pena@sergas.es (R.D.-P.); Tel.: +34-981-955-073 (ext. 15706) (R.D.-P.)
† These authors have contributed equally in this work.

Received: 9 November 2020; Accepted: 13 December 2020; Published: 14 December 2020

Simple Summary: The focus of the genetic studies on rheumatoid arthritis has been on Europeans or European-derived populations, with limited information available on other populations, especially in Latin America. The aim of the present study was to test previously reported HLA markers, the most important genetic contributors for the risk of developing rheumatoid arthritis, associated with anti-citrullinated protein antibodies-positive rheumatoid arthritis in a Latin American population with admixed ancestry. Our study shows for the first time an association between HLA-DRB1*07:01 and *08:02 alleles and protection against anti-citrullinated protein antibodies-positive rheumatoid arthritis in the Chilean population. In addition, our results seem to support the existence of differentiated genomic patterns in Chilean, and probably other Latin American populations, that are not the same that the found in Europeans regarding to loci repeatedly involved in rheumatoid arthritis. Identifying relationships between HLA-DRB1 alleles and rheumatoid arthritis is important for identifying disease associations in different ethnic groups in order to reach a better understanding of rheumatoid arthritis worldwide.

Abstract: HLA-DRB1 shared epitope (SE) alleles are important genetic contributors for the risk of developing anti-citrullinated protein antibodies (ACPA)-positive rheumatoid arthritis (RA), particularly in Caucasians. We aimed to analyze the contribution of HLA-DRB1 alleles and single nucleotide polymorphisms (SNPs) within the major histocompatibility complex (MHC) region to the susceptibility to develop ACPA-positive RA in a Latin American (LA) population with admixed ancestry. A total of 289 ACPA-positive RA patients and 510 controls were enrolled in this study. The presence of HLA-DRB1*04:01, *09:01 and *10:01 was increased in ACPA-positive RA patients compared with healthy controls (p < 0.0001, p < 0.001 and p < 0.01, respectively), whereas DRB1*07:01
and *08:02 was associated with a decreased risk of ACPA-positive RA ($p < 0.001$ and $p < 0.01$, respectively). These results showed a strong correlation with estimates from studies in Asians but not in Caucasian populations. The present study describes the protective effects of the HLA-DRB1*07:01 and *08:02 alleles in ACPA-positive RA patients in a LA population for the first time. Identifying relationships between HLA-DRB1 alleles and RA is important for identifying disease associations in different ethnic groups in order to reach a better understanding of RA worldwide.

**Keywords:** HLA; HLA-DRB1; rheumatoid arthritis; ACPA; Latin American; admixed population

1. Introduction

Rheumatoid arthritis (RA) is a multifactorial, progressive, systemic and inflammatory autoimmune disease that affects approximately 1% of the population worldwide [1]. The prevalence, clinical manifestation and prognosis of RA varies across populations and is influenced by ethnic, socioeconomic, and geographic differences [1]. Most of the studies have been carried out in countries from the North America and North Europe, finding prevalence of 0.5–1.1% [1]. On the other hand, the lowest prevalence values have been found in parts of Asia and Africa, and the highest in Native American populations [1]. Few data are available for developing countries. In Latin America, several studies have been developed in limited regions to a country. This might not be representative of the nation’s prevalence, considering ethnic and cultural differences [2], and genetic variability [3,4], that exist in each country this area of the world. Estimates show a RA prevalence ranging from 0.3 to 2% [5–12].

Since it was first described in 1978 [13], genetic susceptibility to RA has been repeatedly linked to chromosome 6, and specifically to the human “major histocompatibility complex, MHC” (HLA) region. The genes within this region code for paramount proteins involved in the immune defense against invading pathogens. Specifically, MHC class II molecules are present on the membrane of antigen presenting cells (APC). Through these molecules, these APCs display antigens derived from extracellular and membrane proteins, leading to the activation of CD4+ T cells responses. MHC class II proteins are expressed from three gene regions (DR, DQ and DP). Particularly, the HLA-DRB1 shared epitope (SE) has been shown to encode an amino acid sequence largely associated with RA susceptibility and progression ($^{70}$QRRAA$^{74}$, $^{70}$QKRAA$^{74}$, or $^{70}$RRRAA$^{74}$) [14]. The existence of this SE suggests that HLA molecule could bind to molecules similar to bacterial antigens or the named “arthritogenic self-peptides”, hence shaping may drive the T-cell-antigen repertoire to an autoimmune response. Notwithstanding, this arthritogenic peptide remains to be identified.

Anti-citrullinated protein autoantibodies (ACPAs) show high specificity for RA and have become a substantial component of the current ACR-European League Against Rheumatism (EULAR) classification criteria for RA [15]. It has been hypothesized that apoptosis and/or necrosis of pulmonary cells could originate an increased citrullination of proteins in the lungs, due to the increased activation of peptidyl-arginine deiminases enzymes (PAD). The binding of these citrullinated proteins to HLA-DR molecules on APC and their presentation to T cells, followed by B cells activation, may trigger the development of high titters of ACPA. Events so diverse as infection, trauma, exercise, etc., could lead to citrullination of proteins in the joints and the subsequent formation of immune complexes between the citrullinated proteins and ACPA, followed by the binding of immune complexes to the Fc receptors of the synovial macrophages and triggering a chronic inflammatory response.

**HLA-DRB1 gene confers a high polymorphism to the HLA-DR complex** [16]. Since Exon 2 of HLA-DRB1, which encodes the antigen recognition site, is the most variable region, differences in antigen presentation can be largely related to polymorphisms in HLA-DRB1. Interestingly, ethnic differences in the distribution of specific HLA-DRB1 SE alleles worldwide have been reported [17], and these alleles have been shown to be the most important genetic risk factors to develop ACPA-positive RA.
in Caucasians [18]. In turn, in studies in Latin American (LA) populations with a large proportion of European ancestry some HLA-DRB1 alleles have also been associated with RA [18], and also a meta-analysis seemed to revalidate the SE hypothesis in LA populations [19,20]. In spite of this, whether the association of HLA-DRB1 and RA is valid in all ethnic groups remains unclear. In this sense, genome-wide association studies (GWAS) have identified an increasing number of single-nucleotide polymorphisms (SNPs) rendering potential susceptibility to RA in Caucasian and/or Asian populations [21,22]. However, none of these studies GWASs were performed on LA ethnicities [23]. Consequently, the aim of the present study was to analyze the contribution of HLA-DRB1 alleles and SNPs within the MHC region to the susceptibility to develop ACPA-positive RA in the Chilean population, a LA population characterized by a high admixed ancestry.

2. Patients and Methods

2.1. Study Population

A total of 289 RA patients and 510 healthy controls were enrolled in this study. RA patients were consecutive recruited between January 2015 and December 2017 at the Rheumatology Unit of Hospital de Talca, Talca, Chile and at the Rheumatology Unit of the Health Network, the Pontifical Catholic University of Chile, Santiago de Chile, Chile. All RA patients were ACPA-positive and diagnosed following the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria [15]. Patient data were retrospectively analyzed from their anonymized medical records. The control population consisted of 510 matched unrelated healthy blood donors whose samples were collected between January 2015 and May 2020 at Casa del Donante, Talca, Chile and at the CQF Laboratory of the University of Chile (Special Control DNA Biobank), Santiago de Chile, Chile. The study was approved by the Ethical Committee of the “Servicio de Salud del Maule”, Chile (registration Nº04/2014); and all individuals gave their written informed consent prior to enrolling in the study.

2.2. Characterization of HLA-DRB1 Alleles and Levels of ACPA

HLA-DRB1 genotyping was performed using an HLA-SSO typing kit (Tepnel Lifecodes Corporation, Stamford, CT, USA) according to the manufacturer’s instructions. ACPA status was determined by using enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instructions (Euro-Diagnostica AB, Malmö, Sweden). The cut-off value for positivity was set at 25 IU/mL.

2.3. SNP Genotyping

Twenty-four SNPs were chosen for genotyping to check whether previously reported SNP markers within the HLA region (SNPs showing $p < 0.05$, after Bonferroni correction) were associated with RA in LA populations with admixed ancestry [20]. These SNPs were genotyped in our LA admixed population using the OpenArray® TaqMan platform (Applied Biosystems Inc., Waltham, MA, USA) at the Centro Nacional de Genotipado at the Santiago de Compostela node, Spain: rs2027856, rs2157335, rs2239802, rs2395178, rs2395182, rs3104389, rs2858332, rs3129768, rs3129867, rs3129882, rs3129886, rs3129888, rs3139335, rs34102154, rs3998158, rs4959028, rs7775228, rs9268614, rs9268844, rs9271640, rs9275224, rs9275580, rs9275582 and rs9501626.

2.4. Statistical Analysis

The distribution of HLA-DRB1 alleles was compared between RA patients and controls using Fisher’s exact test and two-by-two contingency tables with or without each allele. We used the SPSS v.22 statistical software to estimate the odds ratios (OR) and 95% confidence intervals (95% CI). For comparisons of the HLA-DRB1 allele frequencies, Bonferroni correction was performed by multiplying the $p$ value by the number of DRB1 alleles tested ($n = 36$) to give the corrected $p$-value. The following quality criteria were used for the SNP genotyping data: minor allele frequency (MAF)
<0.01, Hardy–Weinberg equilibrium (HWE) \( p < 0.001 \), and/or missingness >0.1. Allele frequencies were compared between RA patients and controls by Chi-Square analysis, and the OR and 95% CI were calculated using the PLINK software [24].

3. Results

Table 1 displays the characteristics for the 289 RA patients who were enrolled in the present study. The mean age was 48 years and 84.8% of the patients were women, thus confirming the high prevalence of RA in LA women reported in other studies [25]. The mean duration of the disease was 8 years. There were no differences in the sociodemographic parameters between the RA patient and control groups.

Table 1. Characteristics of the patients with rheumatoid arthritis.

| Demographic Characteristics | RA Patients | Healthy Controls |
|-----------------------------|-------------|------------------|
| Women, n (%)                | 245 (84.8)  | 399 (78.2)       |
| Men, n (%)                  | 44 (15.2)   | 111 (21.8)       |
| Age, years (median, range)  | 48 (20–75)  | 42 (25–72)       |

Clinical Parameters

|                         | RA Patients | Healthy Controls |
|-------------------------|-------------|------------------|
| Disease duration, years (median, range) | 8 (1–42) | - |
| Age of onset, years (median, range)       | 40 (15–67) | - |

To investigate the influence of HLA-DRB1 SE alleles on the risk of developing ACPA-positive RA, we genotyped HLA-DRB1 alleles in 289 RA patients and 510 healthy controls. The frequencies of the HLA-DRB1 alleles in the Chilean controls were slightly different from previously reported results [26–28] (Table 2), which was probably due to the diverse origin of the samples from a population with admixed ancestry, most of which is of Mapuche and European origin [4]. HLA-DRB1 SE allele positivity was significantly associated with ACPA-positive RA in the Chilean population [61.8% vs. 33.1%, \( p < 10^{-12} \), OR = 2.28 (2.43–4.44)] (Table 3). Furthermore, the presence of DRB1*04:01, *09:01 and *10:01 was increased in ACPA-positive RA patients compared with healthy controls [\( p < 0.0001 \), \( <0.001 \), and \( <0.01 \) and OR = 3.5 (2.05–5.97), 3.46 (2.01–5.96), and 4.11 (1.98–8.52), respectively], whereas the presence of DRB1*07:01 and *08:02 was associated with a decreased risk of ACPA-positive RA [\( p < 0.001 \), and \( <0.01 \) and 0.30 (0.18–0.52), and 0.09 (0.02–0.38), respectively].

Table 2. Comparison between HLA-DRB1 SE alleles frequencies in previous reports and in our controls from Chile.

| HLA-DRB1 SE Alleles | Frequency |
|---------------------|-----------|
|                     | Our cohort (n = 510) | Schäfer C et al. [26] | Rey D et al. [27] | Thorsby E et al. [28] |
| 01:01               | 0.08       | 0.02       | 0.01       | 0.00       |
| 01:02               | 0.03       | 0.03       | 0.00       | 0.24       |
| 04:01               | 0.04       | 0.01       | 0.00       | 0.05       |
| 04:04               | 0.08       | 0.01       | 0.01       | 0.02       |
| 04:05               | 0.05       | 0.02       | 0.00       | 0.02       |
| 04:08               | 0.02       | 0.01       | 0.00       | 0.00       |
| 10:01               | 0.02       | 0.01       | 0.01       | 0.00       |
| 14:02               | 0.06       | 0.04       | 0.15       | 0.00       |
Table 3. Distribution of HLA–DRB1 alleles in patients with rheumatoid arthritis and healthy controls.

| HLA-DRB1 Allele | RA Cases (n = 289) | Controls (n = 510) | p-Value | BONF | OR (CI 95%) |
|-----------------|-------------------|-------------------|---------|------|-------------|
|                 | n %               | n %               |         |      |             |
| SE-positive†    | 179 61.76         | 169 33.10         | 2.83 x 10^{-15} | 1.02 x 10^{-13} | 2.28 (2.43-4.44) |
| 01:01           | 36 12.35          | 42 8.16           | NS      | NS   |             |
| 01:02           | 10 3.53           | 14 2.82           | NS      | NS   |             |
| 01:03           | 0 0.00            | 4 0.73            | NS      | NS   |             |
| 03:01           | 43 14.71          | 87 16.97          | NS      | NS   |             |
| 03:05           | 0 0.00            | 2 0.36            | NS      | NS   |             |
| 04:01           | 41 14.12          | 23 4.44           | 2.18 x 10^{-6} | 7.85 x 10^{-5} | 3.5 (2.05-5.97) |
| 04:02           | 2 0.59            | 20 3.83           | 0.01    | NS   | 0.17 (0.04-0.74) |
| 04:03           | 2 0.59            | 12 2.37           | NS      | NS   |             |
| 04:04           | 37 12.94          | 42 8.25           | NS      | NS   |             |
| 04:05           | 26 8.82           | 25 4.97           | NS      | NS   |             |
| 04:07           | 19 6.47           | 52 10.27          | NS      | NS   |             |
| 04:08           | 5 1.76            | 11 2.18           | NS      | NS   |             |
| 04:10           | 0 0.00            | 1 0.20            | NS      | NS   |             |
| 07:01           | 17 5.88           | 88 17.33          | 7.08 x 10^{-6} | 2.55 x 10^{-4} | 0.30 (0.18-0.52) |
| 07:11           | 0 0.00            | 2 0.36            | NS      | NS   |             |
| 08:01           | 3 1.18            | 26 5.14           | 5 x 10^{-3} | NS    | 0.20 (0.06-0.65) |
| 08:02           | 2 0.59            | 36 7.05           | 4.2 x 10^{-5} | 1.51 x 10^{-3} | 0.09 (0.02-0.38) |
| 08:06           | 0 0.00            | 1 0.20            | NS      | NS   |             |
| 08:11           | 2 0.59            | 0 0.00            | NS      | NS   |             |
| 09:01           | 39 13.53          | 22 4.48           | 4.44 x 10^{-6} | 1.60 x 10^{-4} | 3.46 (2.01-5.96) |
| 10:01           | 24 8.24           | 11 2.07           | 7.15 x 10^{-5} | 2.57 x 10^{-3} | 4.11 (1.98-8.52) |
| 11:01           | 20 10.00          | 58 11.47          | NS      | NS   |             |
| 11:04           | 0 0.00            | 3 0.59            | NS      | NS   |             |
| 12:01           | 0 0.00            | 6 1.12            | NS      | NS   |             |
| 13:01           | 17 5.88           | 37 7.27           | NS      | NS   |             |
| 13:02           | 14 4.71           | 28 5.50           | NS      | NS   |             |
| 13:03           | 0 0.00            | 5 0.98            | NS      | NS   |             |
| 13:05           | 2 0.59            | 0 0.00            | NS      | NS   |             |
| 14:01           | 22 7.65           | 35 6.85           | NS      | NS   |             |
| 14:02           | 20 7.06           | 29 5.62           | NS      | NS   |             |
| 14:13           | 2 0.59            | 0 0.00            | NS      | NS   |             |
| 15:01           | 19 6.47           | 55 10.77          | NS      | NS   |             |
| 15:02           | 17 5.88           | 27 5.28           | NS      | NS   |             |
| 15:03           | 0 0.00            | 1 0.20            | NS      | NS   |             |
| 16:01           | 0 0.00            | 3 0.59            | NS      | NS   |             |
| 16:02           | 32 11.18          | 58 11.29          | NS      | NS   |             |

HLA-DRB1 shared epitope alleles, including *01:01, *01:02, *04:01, *04:04, *04:05, *04:08, *10:01 and *14:02 alleles.
Abbreviations: NS, not significant; RA, rheumatoid arthritis; SE, shared epitope.

Figure 1 shows the single marker allelic association results of the studied SNPs. Of the 24 SNPs included, four could not be tested because the assay failed in the genotyping phase. (SNPs rs3104389, rs34102154, rs9271640 and rs9275224). The observed genotypic SNP distributions were consistent with Hardy–Weinberg equilibrium (HWE) expectations in both controls and RA patients (p > 0.05). Seven markers exhibited significant association (p ≤ 0.05) with RA after Bonferroni correction (rs3135335, rs3129867, rs2395178, rs9268844, rs9275224, rs9275580, rs3998158; Table S1). The associations of the remaining genes included in the study were not significant. Single-SNP association values in Chile showed similar profiles with estimates from in LA populations with admixed ancestry [20] (Figure 1).
Figure 1. Association results for SNP markers within the HLA region included in this study. The score of the $-\log_{10} \text{Padj}$ values for each SNP association is shown as a continuous line plot. Abbreviations: Padj, p-value using Bonferroni correction.

We also compared the odds ratios of the HLA-DRB1 alleles in our data with reported allelic odds ratios for HLA-DRB1 alleles in a large study of ACPA-positive RA [29] (Figure 2). Specifically, this study included 5018 RA cases and 14974 controls from the UK, Sweden, Canada, and the United States, as well as a South Korean collection of 616 RA cases and 675 controls, all of them being positive for ACPA. There was little correlation between data belonging to Caucasian populations and our data ($r = 0.41$, $p = 0.02$). The effect sizes for each of the HLA-DRB1 alleles were similar with the reported results, except most of the HLA-DRB1 alleles associated with risk of ACPA-positive RA in our study ($\text{DRB1}^*04:01$, $^*07:01$, $^*08:01$, $^*09:01$ and $^*10:01$). On the contrary, our data showed a strong correlation with those from the Korean population ($r = 0.63$, $p = 10^{-4}$). In addition, the effect size of the $\text{DRB1}^*08:02$ allele, whose presence was associated with a decreased risk of ACPA-positive RA (Table 3), was different when compared to the Korean population.

4. Discussion

Many studies have established associations between the susceptibility to ACPA-positive RA and some HLA-DRB1 alleles [18], mainly $\text{DRB1}^*01$, $^*04$ and $^*10$, in Caucasian and Asian populations. However, these studies have not been replicated in populations with a large admixture of Amerindian ancestry. In this study, we analyzed the contribution of HLA-DRB1 alleles to the susceptibility to ACPA-positive RA in the Chilean population.
Figure 2. Correlation between log(odds ratio) from data published in a genome-wide association (GWA) study carried out in Caucasian (A) and Korean (B) populations versus log(odds ratio) reported in this study [29].

Our results showed an association between certain DRB1 alleles and RA susceptibility in the Chilean population. Thus, the frequencies of DRB1*04:01, *09:01 and *10:01 were increased in ACPA-positive RA patients, whereas DRB1*07:01 and *08:02 demonstrated a lower frequency in ACPA-positive RA patients. These results are in line with those reporting genetic associations of RA with HLA-DRB1 SE alleles in LA populations [18]. Moreover, our data also suggest an association between the that ACPA-positive RA and specific HLA polymorphisms from Caucasian and Asian populations. In this sense, DRB1*09:01 confers a strong susceptibility to RA in Asian populations [30]; however, it differs from other SE alleles at position 74, while sharing a common sequence of three Arg as
the DRB1*10:01 susceptibility alleles found in Caucasians. In addition, DRB1*09:01 was associated with the presence of ACPA in individuals with Native American as well as Mexican American ancestry [31]. Surprisingly, the frequency of the HLA-DRB1 alleles in our control population was not similar to previous reports from the Chilean population [26–28]. This could be explained by the fact that the distribution of genetic structure of Chileans is not the same throughout the country [4]. Finally, ORs in Chileans showed little correlation with estimations based in studies made in Europeans, but a strong association with Asians. Since RA is associated with loci involved in immune responses, it is also highly associated with local adaptations and disease resistance. Populations have their own historical particularity, and the exposure to diverse disease factors or traits differs from one to others. Hence, our results seems to support the existence of differentiated genomic patterns in Chilean, and probably other LA populations, that are not the same that the found in Europeans regarding to loci repeatedly involved in RA [32].

The common amino acid sequence at positions 70–74 in the DRβ chain showed an increased RA risk (QKRAA, QRRAA or RRRAA), while alleles that changed from Q/R => D at position 70 exerted a protective effect against RA, especially those alleles containing the 70DERAA sequence, such as DRB1*01:03, *13:01, *13:02 or *04:02. We also observed a trend in the protective role of HLA-DRB1*04:02 in RA susceptibility [31] in the Chilean population. This is relevant, since DRB1*04:02 confers a susceptibility to pemphigus vulgaris (PV) [33], a relatively rare autoimmune disease that is potentially lethal and characterized by blistering of the skin and mucosal membranes. While it is important to define the association of this allele across populations worldwide, the mechanistic basis for the dual role of HLA-DRB1*04:02 in the HLA-disease association, with a protective role in RA and as a genetic risk factor for PV, garners great interest and is not currently understood.

Our study shows for the first time an association between HLA-DRB1*07:01 and *08:02 alleles and protection against ACPA-positive RA in the Chilean population. In 2002, de Vries N et al. reported significant protective effects for DRB1*07 in RA in a study with 167 RA patients and 166 healthy controls, all of whom were Caucasian [34]. More recently, DRB1*07 has been associated with protection against RA in populations of North Africa [31]. Regarding HLA-DRB1*08, this allele was positively associated with systemic lupus erythematosus (SLE) [35] and systemic sclerosis (SSc) [36]. HLA-DRB1*08:02 allele was found associated with bucillamine-induced proteinuria in Japanese RA patients [37]. Similar to methotrexate, d-penicillamine, sulfasalazine, gold salts and anti-malarial drugs, bucillamine is a disease-modifying anti-rheumatic drug (DMARD) frequently used in RA treatment. Further research is needed to define specific the role of this allele in RA.

We analyzed SNPs previously associated with RA in LA populations with admixed ancestry [20] in our test population from Chile. In the previous study by López Herráez et al., 196,524 SNP were genotyped in 1,475 RA patients and 1,213 controls from different LA countries, including 135 patients and 78 controls from a Chilean population. Our results are quite consistent to these previous ones, with 35% of SNP showing a significant association, thus corroborating the complex relationship between HLA and RA in LA populations. On the other hand, we acknowledge that the non-homogeneous origin of the samples and the different size of the sample among populations limit the implications of the results. In this sense, however, single-SNP association values in Chile showed similar profiles compared to LA populations with admixed ancestry described in this study. When the genetic association was examined only in ACPA-positive RA patients [20], the involvement of the HLA region became more significant, particularly for SNP rs9275224 within DQB1/DQA1. Our data revealed the most significant association for the same SNP. GWAS allow us to collect data of single SNP and subsequently infer HLA alleles by HLA imputation in recent studies [38–40]. However, this probably is not recommended in LA populations due to the insufficient information available and the complexity of the admixture. Recently, a GWAS was performed on individuals from four countries in Latin America who were diagnosed as having SLE [41]. HLA allele imputation was performed using the HIBAG program with its corresponding Hispanic reference data set [40]. Efforts to clarify the
role of HLA in RA and the differences in LA populations should be done. So far, classic HLA typing keeps being the best tool.

5. Conclusions

The present study describes for the first time a protective effect of the HLA-DRB1*07:01 and *08:01 alleles in ACPA-positive RA patients of a LA population. It also describes the association of HLA-DRB1 SE alleles commonly found ACPA-positive RA from Asian/Caucasian populations in our LA cohort. Finally, this research seems to support the existence of different genomic patterns in LA populations than those found in Europeans regarding to loci repeatedly associated with RA. These results stress the importance of analyzing the relationships between HLA-DRB1 alleles and RA risk in different ethnic groups to contribute to a better understanding of RA worldwide.

Supplementary Materials: The following are available online at http://www.mdpi.com/2079-7737/9/12/467/s1, Table S1: Single-SNP association values base on the allele frequencies characterized for the RA patients vs. healthy controls.

Author Contributions: Study concept and design, R.D.-P., P.C.-S., J.O. and L.A.Q.; data acquisition, P.C.-S., M.A.G. and C.P.; data analysis, P.C.-S., J.O., R.D.-P. and R.A.V.; data interpretation, R.D.-P., P.C.-S., M.A.G., C.P. and L.A.Q.; funding acquisition, R.D.-P.; investigation, P.C.-S., J.O., R.D.-P. and L.A.Q.; methodology, P.C.-S., J.O., R.A.V., R.D.-P. and L.A.Q.; supervision, R.D.-P. and L.A.Q.; writing—original draft, P.C.-S., J.O., R.D.-P. and L.A.Q.; writing–review and editing, R.D.-P., L.A.Q., P.C.-S., J.O., R.A.V., M.A.G. and C.P. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Fondecyt grant no 11130198.

Conflicts of Interest: No conflict of interest are reported by any of the author.

References

1. Tobón, G.J.; Youinou, P.; Saraux, A. The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. J. Autoimmun. 2010, 35, 10–14. [CrossRef] [PubMed]
2. Sans, M. Admixture studies in Latin America: From the 20th to the 21st century. Hum. Biol. 2000, 72, 155–177. [PubMed]
3. Price, A.L.; Patterson, N.; Yu, F.; Cox, D.R.; Waliszewska, A.; McDonald, G.J.; Tandon, A.; Schirmer, C.; Neubauer, J.; Bedoya, G.; et al. A genomewide admixture map for latino populations. Am. J. Hum. Genet. 2007, 80, 1024–1036. [CrossRef] [PubMed]
4. Eyheramendy, S.; Martinez, F.I.; Manevy, F.; Vial, C.; Repetto, G.M. Genetic structure characterization of Chileans reflects historical immigration patterns. Nat. Commun. 2015, 17, 6472. [CrossRef] [PubMed]
5. Spindler, A.; Bellomio, V.; Berman, A.; Lucero, E.; Baigorria, M.; Paz, S.; Garrone, N.; Torres, A.I.; Romano, O.; Carraccio, A.; et al. Prevalence of rheumatoid arthritis in Tucuman, Argentina. J. Rheumatol. 2002, 29, 1166–1170.
6. Rodrigues Senna, É.; De Barros, A.L.P.; Silva, E.O.; Costa, I.F.; Pereira, L.V.B.; Ciconelli, R.M.; Ferraz, M.B. Prevalence of Rheumatic Diseases in Brazil: A Study Using the COPCORD Approach. J. Rheumatol. 2004, 31, 594–597.
7. Gamboa, R.; Medina, M.; Acevedo, E.; Pastor, C.; Cucho, J.; Gutiérrez, C.; Ugarte, M.; Sánchez, C.; Perich, R.; Alfaro, J.; et al. Prevalencia de enfermedades reumatológicas y discapacidad en una comunidad urbano-marginal: Resultados del primer estudio COPCORD en el Perú. Rev. Peru. Reumatol. 2009, 15, 40–46.
8. Scublinsky, D.; Venarotti, H.; Citera, G.; Messina, O.D.; Scheines, E.; Rillo, O.; Arturi, A.; Hofman, J.; Somma, L.F.; Casado, G.; et al. The prevalence of rheumatoid arthritis in argentina: A capture-recapture study in a city of Buenos Aires Province. J. Clin. Rheumatol. 2010, 16, 317–321. [CrossRef]
9. Pelaez-Ballestas, I.; Sanin, L.H.; Moreno-Montoya, J.; Alvarez-Nemegyei, J.; Burgos-Vargas, R.; Garza-Elizondo, M.; Rodriguez-Amado, J.; Goyochoa-Robles, M.V.; Madariaga, M.; Zamudio, J.; et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J. Rheumatol. 2011, 86, 3–8. [CrossRef]
10. Thorsby, E.; Flm, S.T.; Woldseth, B.; Dupuy, B.M.; Sanchez-Mazas, A.; Fernandez-Vina, M.A. Further evidence of the genetic basis of rheumatoid arthritis: A WHO-ILAR COPCORD study. *Rheumatol. Int.* 2016, 36, 1195–1204. [CrossRef]

11. Granados, Y.; Cedeño, L.; Rosillo, C.; Berbin, S.; Azocar, M.; Molina, M.E.; Lara, O.; Sanchez, G.; Peláez-Ballestas, I. Prevalence of musculoskeletal disorders and rheumatic diseases in an urban community in Monagas State, Venezuela: A COPCORD study. *Clin. Rheumatol.* 2015, 34, 871–877. [CrossRef] [PubMed]

12. Durán, J.; Massardo, L.; Llanos, C.; Iacobelli, S.; Burgos, P.I.; Cisternas, M.; Irurutayena, M.; Armstrong, M.; Aguilera, R.; Radrigán, F.; et al. The Prevalence of Rheumatoid Arthritis in Chile: A Nationwide Study Performed as Part of the National Health Survey. *J. Rheumatol.* 2020, 47, 951–958. [CrossRef] [PubMed]

13. Stastny, P. Association of the B-Cell Alloantigen DRw4 with Rheumatoid Arthritis. *N. Engl. J. Med.* 1978, 298, 869–871. [CrossRef]

14. Gregersen, P.K.; Silver, J.; Winchester, R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. *Arthritis Rheum.* 1987, 30, 1205–1213. [CrossRef]

15. Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.T.; Bingham, C.O.; Birnbaum, N.S.; Burmester, G.R.; Bykerk, V.P.; Cohen, M.D.; et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum.* 2010, 62, 2569–2581. [CrossRef]

16. Robinson, J.; Halliwell, J.A.; Hayhurst, J.D.; Flicek, P.; Parham, P.; Marsh, S.G.E. The IPD and IMGT/HLA database: Allele variant databases. *Nucleic Acids Res.* 2015, D423–D431. [CrossRef] [PubMed]

17. Wysocki, T.; Olesińska, M.; Paradowska-Gorycka, A. Current Understanding of an Emerging Role of the HLA-DRB1 Gene in Rheumatoid Arthritis-From Research to Clinical Practice. *Cells* 2020, 9, 1127. [CrossRef]

18. Castro-Santos, P.; Díaz-Peña, R. Genetics of rheumatoid arthritis: A new boost is needed in Latin American populations. *Rev. Bras. Reumatol.* 2016, 56, 171–177. [CrossRef]

19. Delgado-Vega, A.M.; Anaya, J.-M. Meta-analysis of HLA-DRB1 polymorphism in Latin American patients with rheumatoid arthritis. *Autoimmun. Rev.* 2007, 6, 402–408. [CrossRef]

20. Herráez, D.L.; Martínez-Bueno, M.; Riba, L.; De La Torre, I.G.; Sacnún, M.; Goñi, M.; Berbotto, G.A.; Païra, S.; Musuruanu, J.L.; Graf, C.E.; et al. Rheumatoid arthritis in Latin Americans enriched for Amerindian ancestry is associated with loci in chromosomes 1, 12, and 13, and the HLA Class II region. *Arthritis Rheum.* 2013, 65, 1457–1467. [CrossRef]

21. Okada, Y.; Wu, D.; Trynka, G.; Raj, T.; Terao, C.; Ikari, K.; Kochi, Y.; Ohmura, K.; Suzuki, A.; Yoshida, S.; et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature* 2013, 506, 376–381. [CrossRef] [PubMed]

22. Terao, C.; Raychaudhuri, S.; Gregersen, P.K. Recent Advances in Defining the Genetic Basis of Rheumatoid Arthritis. *Annu. Rev. Genom. Hum. Genet.* 2016, 17, 273–301. [CrossRef] [PubMed]

23. Díaz-Peña, R.; Quiñones, L.A.; Castro-Santos, P.; Durán, J.; Lucia, A. Latin American Genes: The Great Forgotten in Rheumatoid Arthritis. *J. Pers. Med.* 2020, 10, 196. [CrossRef] [PubMed]

24. Purcell, S.; Neale, B.; Todd-Brown, K.; Thomas, L.; Ferreira, M.A.R.; Bender, D.; Maller, J.; Sklar, P.; de Bakker, P.I.W.; Daly, M.J.; et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* 2007, 81, 559–575. [CrossRef]

25. Massardo, L.; Pons-Estel, B.A.; Wojdyla, D.; Cardiel, M.H.; Galazka-Maldonado, C.M.; Sacnún, M.P.; Soriano, E.R.; Laurindo, I.M.; Delgado-Pauta, J.; Lliguisaca-Segarra, A.; Musuruana, J.L.; Graf, C.E.; et al. Rheumatoid arthritis in Latin Americans enriched for Amerindian ancestry is associated with loci in chromosomes 1, 12, and 13, and the HLA Class II region. *Arthritis Rheum.* 2013, 65, 1457–1467. [CrossRef]

26. Schäfer, C.; Sauter, J.; Riethmüller, T.; Kashi, Z.M.; Schmidt, A.H.; Barriga, F.J. HLA-A,-B,-DRB1 allele and haplotype frequencies of 920 cord blood units from Central Chile. *Hum. Immunol.* 2016, 77, 622–623. [CrossRef]

27. Rey, D.; Parga-Lozano, C.; Moscoso, J.; Areces, C.; Enríquez-De-Salamanca, M.; Fernández-Honrado, M.; Abd-El-Fatah-Khalil, S.; Alonso-Rubio, J.; Arnaiz-Villena, A. HLA genetic profile of Mapuche (Araucanian) Amerindians from Chile. *Mol. Biol. Rep.* 2013, 40, 4257–4267. [CrossRef]

28. Thorsby, E.; Flm, S.T.; Woldseth, B.; Dupuy, B.M.; Sanchez-Mazas, A.; Fernandez-Vina, M.A. Further evidence of an Amerindian contribution to the Polynesian gene pool on Easter Island. *Tissue Antigens* 2009, 73, 582–585. [CrossRef]
29. Raychaudhuri, S.; Sandor, C.; Stahl, E.A.; Freudenberg, J.; Lee, H.S.; Jia, X.; Alfredsson, L.; Padyukov, L.; Klæsøk, L.; Worthington, J.; et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. *Nat. Genet.* 2012, 44, 291–296. [CrossRef]

30. Okada, Y.; Kim, K.; Han, B.; Pillai, N.E.; Ong, R.T.H.; Saw, W.Y.; Luo, M.; Jiang, L.; Yin, J.; Bang, S.Y.; et al. Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. *Hum. Mol. Genet.* 2014, 23, 6916–6926. [CrossRef]

31. Karami, J.; Aslani, S.; Jamshidi, A.; Garshashi, M.; Mahmoudi, M. Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review. *Gene* 2019, 702, 8–16. [CrossRef] [PubMed]

32. Castro-Santos, P.; Verdugo, R.A.; Alonso-Arias, R.; Gutiérrez, M.A.; Suazo, J.; Aguillón, J.C.; Olloquequi, J.; Pinochet, C.; Lucia, A.; Quiñones, L.A.; et al. Association analysis in a Latin American population revealed ethnic differences in rheumatoid arthritis-associated SNPs in Caucasian and Asian populations. *Sci. Rep.* 2020, 10, 7879. [CrossRef] [PubMed]

33. Sinha, A.A. The genetics of pemphigus. *Dermatol. Clin.* 2011, 29, 381–391. [CrossRef]

34. De Vries, N.; Tijssen, H.; Van Riel, P.L.C.M.; Van De Putte, L.B.A. Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67–74 of the HLA-DRB1 molecule. *Arthritis Rheum.* 2002, 46, 921–928. [CrossRef] [PubMed]

35. Morris, D.L.; Taylor, K.E.; Fernando, M.M.A.; Nittitham, J.; Alarcón-Riquelme, M.E.; Barcellos, L.F.; Behrens, T.W.; Cotsapas, C.; Gaffney, P.M.; Graham, R.R.; et al. Unraveling multiple MHC gene associations with systemic lupus erythematosus: Model choice indicates a role for HLA alleles and non-HLA genes in Europeans. *Am. J. Hum. Genet.* 2012, 91, 778–793. [CrossRef] [PubMed]

36. Flåm, S.T.; Gunnarsson, R.; Garen, T.; Lie, B.A.; Molberg, O.; Lexberg, Å.S.; Time, K.; Dhainaut, A.S.S.; Bertelsen, L.T.; Palm, O.; et al. The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases. *Rheumatology (UK)* 2015, 54, 528–535.

37. Furukawa, H.; Oka, S.; Shimada, K.; Sugii, S.; Hashimoto, A.; Komiya, A.; Fukui, N.; Miyashita, T.; Migita, K.; Suda, A.; et al. HLA-DRB1*08:02 is associated with Bucillamine-induced proteinuria in Japanese rheumatoid arthritis patients. *Biomark. Insights* 2014, 9, 23–28. [CrossRef] [PubMed]

38. Dilthey, A.T.; Moutsianas, L.; Leslie, S.; McVean, G. HLA*IMP—an integrated framework for imputing classical HLA alleles from SNP genotypes. *Bioinformatics* 2011, 27, 968–972. [CrossRef] [PubMed]

39. Jia, X.; Han, B.; Onengut-Gumuscu, S.; Chen, W.M.; Concannon, P.; Rich, S.S.; Raychaudhuri, S.; de Bakker, P.I.W. Imputing Amino Acid Polymorphisms in Human Leukocyte Antigens. *PLoS ONE* 2013, 8, e64683. [CrossRef]

40. Zheng, X.; Shen, J.; Cox, C.; Wakefield, J.C.; Ehm, M.G.; Nelson, M.R.; Weir, B.S. HIBAG—HLA genotype imputation with attribute bagging. *Pharm. J.* 2014, 14, 192–200. [CrossRef]

41. Alarcón-Riquelme, M.E.; Ziegler, J.T.; Molinero, J.; Howard, T.D.; Moreno-Estrada, A.; Sánchez-Rodríguez, E.; Ainsworth, H.C.; Ortiz-Tello, P.; Comeau, M.E.; Rasmussen, A.; et al. Genome-Wide Association Study in an Amerindian Ancestry Population Reveals Novel Systemic Lupus Erythematosus Risk Loci and the Role of European Admixture. *Arthritis Rheumatol.* 2016, 68, 932–943. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).